At a glance
- Originator Nippon Steel
- Class Anti-ischaemics; Antiplatelets; Oligopeptides; Vascular disorder therapies
- Mechanism of Action GPIIb-IIIa antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Arterial thrombosis; Ischaemic heart disorders